“…It is unknown whether differences in disease mechanism causing nerve pain alter the responsiveness to analgesia. 10 There have been few randomized controlled trials (RCTs) of pharmacotherapeutics for MS pain, and most of those studies have focused on treating trigeminal neuralgia in MS. [11][12][13][14][15] Three RCTs examined the use of cannabinoid derivatives (oral or oropharyngeal spray preparations) for MSrelated pain including dysesthetic limb pain and painful spasms. The studies found some evidence of effectiveness in pain relief, but the utility of these medications is limited by safety concerns, adverse effects, and their status with the Drug Enforcement Agency.…”